Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Question Of Omecamtiv, Sotorasib Filing Plans Unanswered

 
• By Mandy Jackson
  
Abstract mash line and point Question mark. Business illustration. Polygonal low poly
Amgen left questions unanswered regarding sotorasib, omecamtiv and tezepelumab
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business